Latest Scripps Research Stories
Ads in Craigslist lead to potential medical advance Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way. The antibody recognizes the crucial structure that flu viruses use to attach to host cells, even though previously this structure had been thought too small for an antibody to grab effectively. The immune protein manages to hit this precise spot by using...
For Scripps Research, the Focused Deal Provides a Model for Future LA JOLLA, Calif., June 15, 2012 /PRNewswire-USNewswire/ -- The Scripps Research Institute today announced it has entered into a five-year collaboration with Bristol-Myers Squibb Company (NYSE:BMY) focused on applying novel chemistry to drug discovery and synthesis. The collaboration will revolve around support for projects of mutual interest to Bristol-Myers Squibb and a number of Scripps Research chemistry...
LA JOLLA, Calif., May 31, 2012 /PRNewswire/ -- Scripps Research Institute Professor Richard A. Lerner, MD, has won a prestigious international honor, the Prince of Asturias Award for Scientific and Technical Research, according to an announcement made today by the Prince of Asturias Foundation. Lerner shares the award with British biochemist Sir Gregory Winter, PhD. Sometimes called the "Spanish Nobel Prize," the Prince of Asturias Award for Scientific and Technical Research is...
New Drug Helps Pre-Term Infants Breathe LA JOLLA, Calif., March 6, 2012 /PRNewswire-USNewswire/ -- Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin® (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome. "I am excited that our scientific findings will help save lives," said Charles Cochrane, M.D., professor emeritus at Scripps Research. "Many years of work in our basic...
The new approach could have implications for many genetic diseases While RNA is an appealing drug target, small molecules that can actually affect its function have rarely been found. But now scientists from the Florida campus of The Scripps Research Institute have for the first time designed a series of small molecules that act against an RNA defect directly responsible for the most common form of adult-onset muscular dystrophy. In two related studies published recently in...
Team develops first 3D look at interaction between immune sensor and protein that helps bacteria move To invade organisms such as humans, bacteria make use of a protein called flagellin, part of a tail-like appendage that helps the bacteria move about. Now, for the first time, a team led by scientists at The Scripps Research Institute and Sanford-Burnham Medical Research Institute has determined the 3D structure of the interaction between this critical bacterial protein and an immune...
The findings advance AIDS vaccine development Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development. "What's unexpected and unique about this antibody is that it not only attaches to the sugar coating of the virus but also reaches through to grab...
The Findings Advance AIDS Vaccine Development LA JOLLA, Calif., Oct. 13, 2011 /PRNewswire-USNewswire/ -- Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development. "What's unexpected and unique about this antibody is that it not only attaches to the sugar...
The Work Provides Insight into Potential Therapeutic for Cancer and Eye DiseasesAn enzyme that normally helps break down stored fats goes into overdrive in some cancer cells, making them more malignant, according to new findings by a team at The Scripps Research Institute."Historically, research has focused on the mechanisms leading to cancer formation and therapies have focused on taking out cancer cells," says Benjamin Cravatt, chair of the Scripps Research Department of Chemical...
A research team at the Scripps Research Institute has obtained the first glimpse of a protein that keeps certain substances, including many drugs, out of cells. The protein, called P-glycoprotein or P-gp for short, is one of the main reasons cancer cells are resistant to chemotherapy drugs. Understanding its structure may help scientists design more effective drugs.The new research was described in the March 27, 2009, issue of the journal Science."This structure is an important advance...
